MMSI Stock Forecast & Price Target

Merit Medical Systems is supported by a credible growth profile, with management on track to meet or exceed the 2024E-2026E CGI plan through an implied 6.6% organic revenue CAGR, a 2026E operating margin of 21.2%, and cumulative free cash flow of $634M versus a $400M target. Its outlook is further strengthened by margin expansion, as gross margin is expected to rise from 50.4% in 2023A to 54.0% in 2026E while the mix shifts toward faster-growing Therapeutic Products, which have outpaced Foundational Products over the last three years. The company also has strong capital-allocation flexibility, with a balance sheet that supports tuck-in acquisitions and possible share repurchases, while healthy U.S. and European demand and resilient cardiovascular end markets reinforce the long-term case.

Merit Medical Systems is facing a bearish setup because revenue growth of 5% or lower is tied to worsening contribution from recent acquisitions and unsuccessful new product launches. Those headwinds would likely pressure operating margins further and leave earnings below consensus, undermining the company’s ability to translate its Cardiovascular-led revenue base into stronger profitability. The valuation framework also reflects this risk, as the scenario uses a roughly 13x P/E on the 2027E adjusted EPS estimate, implying investors may continue to discount execution and growth durability.